Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia/myelodysplastic syndrome not in remission.
Wen YaoXiandeng ChuXinchen FangXiaoyu ZhuBaolin TangXiang WanLiangquan GengJuan TongKaidi SongXuhan ZhangPing QiangGuangyu SunHuilan LiuZimin SunPublished in: Journal of clinical pharmacy and therapeutics (2020)
Our results suggest that addition of decitabine as part of the myeloablative conditioning regimen prior to UCBT for refractory/relapsed AML/MDS in patients who are not in remission is safe and might be an effective treatment option.
Keyphrases
- acute myeloid leukemia
- cord blood
- allogeneic hematopoietic stem cell transplantation
- disease activity
- liver failure
- ulcerative colitis
- stem cell transplantation
- acute lymphoblastic leukemia
- respiratory failure
- rheumatoid arthritis
- stem cells
- bone marrow
- systemic lupus erythematosus
- dendritic cells
- mesenchymal stem cells
- diffuse large b cell lymphoma
- aortic dissection
- low dose
- immune response
- hodgkin lymphoma
- acute respiratory distress syndrome